Egle Therapeutics to highlight novel preclinical findings for regulatory T cells targeting programs EGL-001 and EGL-002 with poster presentations at the 2025 AACR Annual Meeting
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual…